Wechselwirkungen von Natriumpolystyrolsulfonat

Potassium supplementation in the form of medication, potassium-containing salt substitutes or a potassium-rich diet should not be used with amiloride HCl except in severe and/or refractory cases of hypokalemia. (Fachinformation zu Amilorid, Gegenanzeigen)

Cation-Donating Antacids The simultaneous oral administration of Sodium Polystyrene Sulfonate Powder, for Suspension with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis 7.3 Sorbitol Sorbitol may contribute to the risk of intestinal necrosis [ see Warnings and… (Fachinformation zu Natriumpolystyrolsulfonat, Arzneimittelwechselwirkungen)

…with: • type 2 diabetes with microalbuminuria, • serum creatinine > 2.0 mg/dL in males or >1.8 mg/dL in females, • creatinine clearance < 50 mL/min, or • concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene) [see Warnings and Precautions (5.1) , Adverse Reactions (6.2) , Drug Interactions… (Fachinformation zu Eplerenon, Gegenanzeigen)

• GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride : Concomitant use is not recommended. (Fachinformation zu Glycopyrroniumbromid, Arzneimittelwechselwirkungen)

Information for patients Patients who receive spironolactone and hydrochlorothiazide tablets should be advised to avoid potassium supplements and foods containing high levels of potassium including salt substitutes. (Fachinformation zu Spironolacton und Hydrochlorothiazid, Vorsichtsmaßnahmen)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes, combination use with ARBs or ACEIs [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 ), and Clinical Studies ( 14.3 )] , NSAIDs, or potassium supplements or potassium sparing diuretics. (Fachinformation zu Aliskiren, Warnhinweise und Vorsichtsmaßnahmen)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes. (Fachinformation zu Amlodipin und Benazepril, Warnhinweise und Vorsichtsmaßnahmen)

…Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart… (Fachinformation zu Amlodipin und Valsartan, Arzneimittelwechselwirkungen)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (Fachinformation zu Benazepril, Warnhinweise und Vorsichtsmaßnahmen)

Cation-Donating Antacids The simultaneous oral administration of Sodium Polystyrene Sulfonate Powder, for Suspension with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis 7.3 Sorbitol Sorbitol may contribute to the risk of intestinal necrosis [ see Warnings and… (Fachinformation zu Natriumpolystyrolsulfonat, Arzneimittelwechselwirkungen)

Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (Fachinformation zu Candesartan, Arzneimittelwechselwirkungen)

Co-administration of candesartan cilexetil and hydrochlorothiazide tablets with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (Fachinformation zu Candesartan und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. (Fachinformation zu Captopril, Arzneimittelwechselwirkungen)

Caution is also required when cyclosporine is coadministered with potassium sparing drugs (e.g., angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists), potassium-containing drugs as well as in patients on a potassium rich diet. (Fachinformation zu Ciclosporin, Arzneimittelwechselwirkungen)

Cation-Donating Antacids The simultaneous oral administration of Sodium Polystyrene Sulfonate Powder, for Suspension with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis 7.3 Sorbitol Sorbitol may contribute to the risk of intestinal necrosis [ see Warnings and… (Fachinformation zu Natriumpolystyrolsulfonat, Arzneimittelwechselwirkungen)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions ( 7.3 )]. (Fachinformation zu Enalapril, Warnhinweise und Vorsichtsmaßnahmen)

Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. (Fachinformation zu Enalapril und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. (Fachinformation zu Enalaprilat, Arzneimittelwechselwirkungen)

Monitor serum potassium levels; use potassium supplements if necessary. (Fachinformation zu Fludrocortison, Arzneimittelwechselwirkungen)

Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia. (Fachinformation zu Fosinopril, Arzneimittelwechselwirkungen)

Drug Interactions Potassium supplements and potassium-sparing diuretics As noted above (“Derangements of Serum Electrolytes”), the net effect of fosinopril sodium and hydrochlorothiazide may be to elevate a patient’s serum potassium, to reduce it, or to leave it unchanged. (Fachinformation zu Fosinopril und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Coadministration of AVALIDE with potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia, sometimes severe. (Fachinformation zu Irbesartan und Hydrochlorothiazid, Warnhinweise und Vorsichtsmaßnahmen)

Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (Fachinformation zu Kaliumiodid, Arzneimittelwechselwirkungen)

Cation-Donating Antacids The simultaneous oral administration of Sodium Polystyrene Sulfonate Powder, for Suspension with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis 7.3 Sorbitol Sorbitol may contribute to the risk of intestinal necrosis [ see Warnings and… (Fachinformation zu Natriumpolystyrolsulfonat, Arzneimittelwechselwirkungen)

Drug or Drug Class Effect Bile Acid Sequestrants -Colesevelam -Cholestyramine -Colestipol Ion Exchange Resins -Kayexalate -Sevelamer Bile acid sequestrants and ion exchange resins are known to decrease thyroid hormones absorption. (Fachinformation zu Liothyronin, Arzneimittelwechselwirkungen)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (Fachinformation zu Lisinopril, Warnhinweise und Vorsichtsmaßnahmen)

Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. (Fachinformation zu Lisinopril und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Decreased absorption of lithium and thyroxine have also been reported with co-administration of Sodium Polystyrene Sulfonate Powder, for Suspension. (Fachinformation zu Natriumpolystyrolsulfonat, Arzneimittelwechselwirkungen)

Cation-Donating Antacids The simultaneous oral administration of Sodium Polystyrene Sulfonate Powder, for Suspension with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis 7.3 Sorbitol Sorbitol may contribute to the risk of intestinal necrosis [ see Warnings and… (Fachinformation zu Natriumpolystyrolsulfonat, Arzneimittelwechselwirkungen)

Potassium Supplements and Potassium-Sparing Diuretics: Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. (Fachinformation zu Moexipril, Arzneimittelwechselwirkungen)

Cation-Donating Antacids: may reduce the resin’s potassium exchange capability and increase risk of systemic alkalosis ( 7.2 ). (Fachinformation zu Natriumpolystyrolsulfonat, Arzneimittelwechselwirkungen)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.3) ] . (Fachinformation zu Olmesartan, Warnhinweise und Vorsichtsmaßnahmen)

Cation-Donating Antacids: may reduce the resin’s potassium exchange capability and increase risk of systemic alkalosis ( 7.2 ). (Fachinformation zu Natriumpolystyrolsulfonat, Arzneimittelwechselwirkungen)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus and the concomitant use of agents such as potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.2) ] . (Fachinformation zu Perindopril, Warnhinweise und Vorsichtsmaßnahmen)

Potassium-Sparing Diuretics As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium [see Warnings and Precautions (5.5)] . (Fachinformation zu Sacubitril und Valsartan, Arzneimittelwechselwirkungen)

Cation-Donating Antacids The simultaneous oral administration of Sodium Polystyrene Sulfonate Powder, for Suspension with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis 7.3 Sorbitol Sorbitol may contribute to the risk of intestinal necrosis [ see Warnings and… (Fachinformation zu Natriumpolystyrolsulfonat, Arzneimittelwechselwirkungen)

This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

Hyperkalemia Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. (Fachinformation zu Telmisartan, Warnhinweise und Vorsichtsmaßnahmen)

Hyperkalemia Telmisartan Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. (Fachinformation zu Telmisartan und Amlodipin, Warnhinweise und Vorsichtsmaßnahmen)

Sodium Polystyrene Sulfonate (SPS): Separate administration by at least three hours ( 7.2 ). (Fachinformation zu Tenapanor, Arzneimittelwechselwirkungen)

Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. (Fachinformation zu Trandolapril, Arzneimittelwechselwirkungen)

Sodium polystyrene sulfonate may be administered to enhance the excretion of excess potassium. (Fachinformation zu Triamteren, Warnhinweise und Vorsichtsmaßnahmen)

Exchange resins, such as sodium polystyrene sulfonate, whether administered orally or rectally, reduce serum potassium levels by sodium replacement of the potassium; fluid retention may occur in some patients because of the increased sodium intake. (Fachinformation zu Triamteren und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine ( 7.1 ) (Fachinformation zu Valsartan, Arzneimittelwechselwirkungen)

…Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart… (Fachinformation zu Valsartan und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Interactions Common for Both Benazepril and Hydrochlorothiazide Potassium Supplements and Potassium -Sparing Diuretics: Concomitant use with Lotensin HCT may effect potassium levels. (Fachinformation zu Benazepril und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Supplemental potassium and/or spironolactone may prevent hypokalemia and metabolic alkalosis in these patients. (Fachinformation zu Bumetanid, Warnhinweise)

Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen. (Fachinformation zu Dobutamin, Arzneimittelwechselwirkungen)

Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride. (Fachinformation zu Hyoscyamin, Arzneimittelwechselwirkungen)

…been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. (Fachinformation zu Milrinon, Arzneimittelwechselwirkungen)